Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines.
Chronic lung disease
Palivizumab immunoprophylaxis
Respiratory syncytial virus
Treatment utilization pattern
Journal
European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
10
03
2021
accepted:
02
08
2021
revised:
31
07
2021
pubmed:
9
8
2021
medline:
10
2
2022
entrez:
8
8
2021
Statut:
ppublish
Résumé
Guidelines from the American Academy of Pediatrics recommend palivizumab immunoprophylaxis for children with CLD in their second year of life if they continue to need treatment within 6 months before the RSV season. The utilization patterns of treatment (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) are not well understood. We examined variations in CLD treatment for ten consecutive 20-day segments preceding RSV season onset. Among infants and children with CLD (n = 19,026), 35.2% received one or more medical treatments for CLD any time within 200 days before entering the second RSV season: 8.6%, 3.2%, and 29.7% received supplemental oxygen, diuretics, and corticosteroids, respectively. Utilization decreased as infants' age increased with corticosteroids surpassing oxygen and diuretics. To avoid the capture of intermittent use of corticosteroids for acute infections, we found requiring a minimum of 45 days cumulative exposure was reasonable to determine chronic use. What is Known: • Guidelines from the American Academy of Pediatrics recommend palivizumab immunoprophylaxis for children with CLD in their second year of life if they continue to need treatment within 6 months before the RSV season. • The utilization patterns of treatment (chronic corticosteroid therapy, diuretic therapy, or supplemental oxygen) are not well understood. A definition of chronic corticosteroid therapy in this setting is not available. What is New: • Among infants and children with CLD of prematurity, 35.2% received one or more medical treatments for CLD any time within 200 days before entering the second RSV season: 8.6%, 3.2%, and 29.7% received oxygen, diuretics, and corticosteroids, respectively. Utilization decreased as infants' age increased with corticosteroids surpassing oxygen and diuretics. • A minimum of 45 days cumulative corticosteroid use within the past 90 days would accurately capture chronic use to fulfill criteria for immunoprophylaxis while limiting the inclusion of intermittent use of corticosteroids for acute infections.
Identifiants
pubmed: 34365543
doi: 10.1007/s00431-021-04233-6
pii: 10.1007/s00431-021-04233-6
pmc: PMC8349231
doi:
Substances chimiques
Antiviral Agents
0
Palivizumab
DQ448MW7KS
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
841-845Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Committee on Infectious Diseases (2014) Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134(2):e620-638
doi: 10.1542/peds.2014-1666
Florida Department of Health (2015) Certificates—birth, death, fetal death, marriage and divorce. Available at https://www.dshs.texas.gov/vs/ . Accessed 1 July 2015
Texas Health and Human Services (2015) Texas vital statistics. Available at http://www.floridahealth.gov/certificates/certificates/ . Accessed 1 July 2015
National Center for Health Statistics (2021) Birth Data. Available at https://www.cdc.gov/nchs/fastats/state-and-territorial-data.htm . Accessed 29 July 2021
The Kaiser Family Foundation (2007) Medicaid’s role in family planning. Available at https://www.guttmacher.org/sites/default/files/pdfs/pubs/IB_medicaidFP.pdf . Accessed 15 Mar 2017
Sonfield A, Kost K, Gold RB, Finer LB (2011) The public costs of births resulting from unintended pregnancies: national and state-level estimates. Perspect Sex Reprod Health 43(2):94–102
doi: 10.1363/4309411
Landry JS, Croitoru D, Menzies D (2012) Validation of ICD-9 diagnostic codes for bronchopulmonary dysplasia in Quebec’s provincial health care databases. Chronic Dis Inj Can 33(1):47–52
doi: 10.24095/hpcdp.33.1.06
Choi Y, Meissner HC, Hampp C, Park H, Brumback B, Winterstein AG (2020) Calibration of chronic lung disease severity as a risk factor for respiratory syncytial virus hospitalization. J Ped Infect Dis Soc 10(3):317-25
Baveja R, Christou H (2006) Pharmacological strategies in the prevention and management of bronchopulmonary dysplasia. Semin Perinatol 30(4):209–218
doi: 10.1053/j.semperi.2006.05.008
Crystal S, Akincigil A, Bilder S, Walkup JT (2007) Studying prescription drug use and outcomes with medicaid claims data: strengths, limitations, and strategies. Med Care 45(10 Supl 2):S58–65
Shinwell ES, Portnov I, Meerpohl JJ, Karen T, Bassler D (2016) Inhaled corticosteroids for bronchopulmonary dysplasia: a meta-analysis. Pediatrics 1;138(6):e20162511
Olsen SJ, Winn AK, Budd AP et al (2020–2021) Changes in influenza and other respiratory virus activity during the Covid-19 pandemic-United States. MMWR 70(29):1013–1019